Erasca, Inc.

Industry · 9 registered clinical trials — 2 currently recruiting.

Status	Trial	Phase	Started
Recruiting	A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. Metastatic Solid Tumors	Phase 1	2025-08-06
Recruiting	A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors Metastatic Solid Tumors	Phase 1	2025-06-05
Active Not Recruiting	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (S Advanced or Metastatic NRAS-mutant Melanoma	Phase 3	2024-04-29
Active Not Recruiting	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations Advanced or Metastatic Solid Tumors	Phase 1	2023-08-17
Withdrawn	A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies Acute Myeloid Leukemia	Phase 1 / Phase 2	2022-03-15
Completed	A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma	Phase 1 / Phase 2	2021-09-20
Completed	A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC Advanced Non-squamous Non-small-cell Lung Cancer	Phase 1	2021-09-02
Active Not Recruiting	A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Sol Advanced or Metastatic Solid Tumors	Phase 1 / Phase 2	2021-05-07
Active Not Recruiting	A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors Advanced or Metastatic Solid Tumors	Phase 1	2020-12-15